Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Eric Andrew Collisson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8037-9388; OpenAlex author ID A5035793503; NIH RePORTER profile ID 9233486. Sources: OpenAlex.

Their work

Papers
33 (first author 3, last author 4)
Trials
0
Grants
6
Labs led
2
Collaborators
131
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper, 1 grant · 2013: 1 paper · 2014: 1 paper, 1 grant · 2015: 1 paper, 1 grant · 2016: 3 papers · 2017: 5 papers · 2018: 3 papers, 1 grant · 2019: 3 papers · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper, 1 grant · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper, 1 grant

Papers 33

  1. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  2. AI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication. Co-author DOI 10.1007/s00261-024-04775-x↗
  3. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  4. Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/s41591-023-02694-w↗
  5. RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming. First author DOI 10.1007/s11864-023-01096-x↗
  6. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Last author DOI 10.1016/j.xcrm.2023.101013↗
  7. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism. Co-author DOI 10.1053/j.gastro.2021.09.066↗
  8. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13968↗
  9. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  10. A Novel Model of Pancreatic Cancer Dormancy Reveals Mechanistic Insights and a Dormancy Gene Signature with Human Relevance Co-author DOI 10.1101/2020.04.13.037374↗
  11. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0268↗
  12. Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1062↗
  13. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Last author DOI 10.1172/jci136760↗
  14. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.22462↗
  15. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s10689-018-0106-2↗
  16. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Co-author DOI 10.1038/s41467-019-11044-9↗
  17. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  18. The Role of MR Imaging in Pancreatic Cancer. Co-author DOI 10.1016/j.mric.2018.03.004↗
  19. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. Last author DOI 10.1200/po.17.00121↗
  20. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. Last author DOI 10.2214/ajr.18.19602↗
  21. Pancreatic Cancer Genomics 2.0: Profiling Metastases. Co-author DOI 10.1016/j.ccell.2017.02.014↗
  22. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  23. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Co-author DOI 10.1073/pnas.1620164114↗
  24. Advances in the Genetics and Biology of Pancreatic Cancer. First author DOI 10.1097/ppo.0000000000000286↗
  25. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenoca… Co-author DOI 10.18632/oncotarget.22080↗
  26. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.06.017↗
  27. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/nm.4082↗
  28. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-0979↗
  29. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Co-author DOI 10.1101/gad.256628.114↗
  30. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗
  31. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. First author DOI 10.1158/1535-7163.mct-13-0104↗
  32. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-11-0347↗
  33. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Co-author DOI 10.1038/nm.2344↗

Grants 6

  1. Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy R01CA256969↗
  2. Tailoring Therapy to Pancreatic Cancer Subtypes R01CA222862↗
  3. Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis R01CA178015↗
  4. A Genetically Defined System to Identify Factors Essential for KRas Oncogenesis R21CA176561↗
  5. A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma K08CA137153↗
  6. Optimizing MEK Inhibition in Pancreatic Cancer; from Cytostatic to Cidal AWARD pancan:2012-eric-collisson-md-optimizing-mek-inhibition-in-pancreatic-

Closest collaborators

The 25 strongest of 131 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen J. Wang · 4 shared papers, 1 shared grant, 2018–2026 · strength 1.39
  2. Ajit Harishkumar Goenka · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.27
  3. Margaret A. Tempero · 8 shared papers, 2011–2021 · strength 0.65
  4. Lisa Miller‐Phillips · 2 shared papers, 2023–2025 · strength 0.57
  5. Andrew H. Ko · 7 shared papers, 2011–2021 · strength 0.54
  6. Julia Sidenius Johansen · 5 shared papers, 2016–2024 · strength 0.49
  7. Grace Kim · 4 shared papers, 2011–2025 · strength 0.41
  8. Benjamin M. Yeh · 4 shared papers, 2018–2020 · strength 0.39
  9. Jen Jen Yeh · 3 shared papers, 2018–2025 · strength 0.34
  10. Davendra P. S. Sohal · 2 shared papers, 2023–2026 · strength 0.33
  11. Vivek U. Nimgaonkar · 2 shared papers, 2023–2026 · strength 0.33
  12. Andrew Eugene Hendifar · 2 shared papers, 2023–2026 · strength 0.33
  13. Christos K Fountzilas · 2 shared papers, 2023–2026 · strength 0.33
  14. Aatur Dilip Singhi · 2 shared papers, 2023–2026 · strength 0.33
  15. Michael Anthony Hollingsworth · 4 shared papers, 2018–2021 · strength 0.31
  16. Valerie Marie Weaver · 3 shared papers, 2016–2024 · strength 0.29
  17. Sovanlal Mukherjee · 1 shared paper, 2025 · strength 0.27
  18. Ajith Antony · 1 shared paper, 2025 · strength 0.27
  19. Michael B. Wallace · 1 shared paper, 2025 · strength 0.27
  20. Yan Bi · 1 shared paper, 2025 · strength 0.27
  21. Honglin Jiang · 2 shared papers, 2020–2022 · strength 0.26
  22. Nilotpal Roy · 3 shared papers, 2015–2024 · strength 0.25
  23. Matthias Hebrok · 3 shared papers, 2015–2024 · strength 0.25
  24. Ronald M. Evans · 4 shared papers, 2014–2021 · strength 0.23
  25. Julia C. Carnevale · 2 shared papers, 2019–2021 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.